1266084-51-8

In uninfected mice, 4.3 mg/kg intravenous dose of Acoziborole show an apparent elimination half-life (t_1/2) of 26.6 h; systemic clearance (CL) of 0.089 L/h/kg; a volume of distribution (Vd_ss) of 1.69 L/kg and area under the concentration-time curve (AUC_{0-24 h}) of 48 h?μg/mL. Following an oral dose of 13.4 mg/kg, which corresponds to the lowest efficacious dose in the murine stage 2 HAT model, Acoziborole is rapidly absorbed, as a C_max of 6.96 μg/mL is achieved in plasma at 6 h after dose, with an oral clearance (Cl/F) value of 0.163 L/h/kg, an AUC_{0-24 h} of 82 h?μg/mL and absolute oral bioavailability of 55%. After a 26 mg/kg oral dose, which corresponds to the dose giving a 100% cure rate in the murine stage 2 HAT model, C_max increases to 9.8 μg/mL and the AUC_{0-24 h} is 113 h?μg/mL. In uninfected rats, following oral administration of Acoziborole at a nominal dose of 25 mg/kg (dose affording a 100% cure rate in mice), C_max increases approximately 2 fold more than that in mice (C_max=18.2 μg/mL) and AUC_{0-24 h}, and hence oral clearance, improves approximately 4 fold (AUC_{0-24 h} 291 h?μg/mL and CL/F=0.092 L/kg/h). The time to maximum concentration is similar to that in mice (t_max=8 h). Uninfected male and female cynomolgus monkeys are treated with Acoziborole at 2 mg/kg (IV) on study day 1 and 10 mg/kg (NG) on study day 8. Acoziborole exhibits excellent plasma pharmacokinetics, with CL of 0.022 L/h/kg; Vd_ss of 0.656 L/kg and area under the concentration-time curve 78.8 h?μg/mL, and 94.4 for AUC_{0-24 h} and AUC_0-inf, respectively, following intravenous administration^[1].